Weiping Zang, MD
Hematology & Oncology · Cincinnati, OHNPI 1366722787
Payments from drug & device makers
Across 34 payments — averaging $34.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$243
- Boston Scientific$164
- Pfizer$148
- Genentech USA, Inc.$119
- Amgen$51
- AbbVie$49
- plus $409 from 14 others
What the payments were for
- Food & beverage$1,02987%
- Education$15313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $243 |
| Boston Scientific | 1 | $164 |
| Pfizer | 3 | $148 |
| Genentech USA, Inc. | 3 | $119 |
| Amgen | 3 | $51 |
| AbbVie | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Exelixis Inc. | 1 | $46 |
| Sanofi | 2 | $46 |
| Novartis | 3 | $43 |
| Merck | 2 | $37 |
| Spectrum Pharmaceuticals Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Tempus AI, Inc | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| CTI Biopharma Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,182 in reported general payments places this provider in the 30th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 30 | $696,361 |
| JakafiRuxolitinib Phosphate | 23 | $400,135 |
| CalquenceAcalabrutinib Maleate | 23 | $356,278 |
| Lenalidomide | 19 | $272,937 |
| PomalystPomalidomide | 11 | $215,229 |
| CaprelsaVandetanib | 11 | $203,405 |
| ImbruvicaIbrutinib | 13 | $147,888 |
| TafinlarDabrafenib Mesylate | 11 | $128,542 |
| EliquisApixaban | 81 | $103,597 |
| Abiraterone Acetate | 16 | $29,175 |
| XareltoRivaroxaban | 14 | $22,880 |
| Anastrozole | 102 | $1,798 |
| Potassium Chloride | 28 | $1,094 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $1,011 |
| Hydroxyurea | 34 | $967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $243 | $356,27823 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $48 | $215,22911 claims |
| SanofiCaprelsa | $46 | $203,40511 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $25 | $147,88813 claims |
| NovartisTafinlar | $43 | $128,54211 claims |
| PfizerEliquis | $148 | $103,59781 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- David WaterhouseCincinnati$5.7M
- Patrick WardCincinnati$3.8M
- James EssellCincinnati$3.7M
- Edward FaberCincinnati$2.3M
- Omar AlkharabshehCincinnati$1.2M
- Alexander StarodubCincinnati$1.1M
- Mark JohnsCincinnati$999K
- Jason JonesCincinnati$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.